WS6

WS6 is an IkB kinase and EBP1 inhibitor, with IC₅₀ values of 0.24 nM, 0.21 nM, and 40.48 nM in MV4-11, MOLM13, and K562 cells, respectively. WS6 promotes the proliferation of alpha and beta cells in the pancreas, has antioxidant and anti-inflammatory activities, and can alleviate depression like behavior in rats^[1][2][4].
IC50 & Target:EBP1, IkB^[1]. In Vitro:WS6 (1 μM, 48 h) stimulates the proliferation of alpha and beta cells in human pancreatic islets while maintaining cell viability and beta cell differentiation phenotype^[1].
WS6 (0-30 μM, 72 h) reduces MYCN protein stability and neuroblastoma tumorigenicity by inhibiting PA2G4 and MYCN protein binding^[3].
WS6 (0-1 μM, 72 h) overcomes drug resistance and kills FLT3-ITD AML primitive cells by targeting FLT3-ITD driven kinase in acute myeloid leukemia (AML)^[4].
WS6 (0.1, 0.5 μM, 15 min) promotes cell proliferation in the cochlea of neonatal mice by activating ERBB2 phosphorylation and PI3K activity, and enhancing EGFR family signaling^[5].
WS6 exhibits better pharmacokinetic characteristics and binding strength with acetylcholinesterase and neurotrophic factors in computer simulations, thus having the potential to treat Alzheimer's disease^[6].
In Vivo:WS6 (2.2 mg/kg; once a day; 28 days; i.p.) alleviates depression like behavior in rats by enhancing GABA signaling and dendritic density in the hippocampus of chronic unpredictable mild stress (CUMS) model rats^[2].